Role of kynurenines in the neurotoxic actions of kainic acid

British Journal of Pharmacology

Volumn 129, Issue 8, 2000, Pages 1764-1770

  Behan, W M H ^a   Stone, T W ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Excitotoxicity; Glycine; Hippocampus; Kainic acid; Kynurenic acid; Kynurenines; Quinolinic acid

Indexed keywords

ALANINE DERIVATIVE; DIZOCILPINE; GLYCINE; KAINIC ACID; KYNURENINASE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITROBENZENE DERIVATIVE; OXYGENASE INHIBITOR; QUINOLINIC ACID;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; HIPPOCAMPUS; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033997130     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703250     Document Type: Article

References (55)

1. ALBERATIGIANI, D. & CESURA, A.M. (1998). Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators. Amino Acids, 14, 251-255.
2. ALBERATIGIANI, D., RICCIARDICASTAGNOLI, P., KOHLER, C. & CESURA, A.M. (1996). Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J. Neurochem., 66, 996-1004.
3. BEHAN, W.M.H., MCDONALD, M., DARLINGTON, L.G. & STONE, T.W. (1999). Oxidative stress as a mechanism for quinolinic acid induced hippocampal damage: protection by melatonin and deprenyl. Brit. J. Pharmacol., 128, 1754-1760.
4. BERG, M., BRUHN, T., JOHANSEN, F.F. & DIEMER, N.H. (1993). Kainic acid-induced seizures and brain damage in the rat: different effects of NMDA- and AMPA receptor antagonist. Pharmacol. Toxicol., 73, 262-268.
5. BERMAN, F.W. & MURRAY, T.F. (1997). Domoic acid neurotoxicity in cultured cerebellar granule neurons is mediated predominantly by NMDA receptors that are activated as a consequence of excitatory amino acid release. J. Neurochem., 69, 693-703.
6. BIRCH, P.J., GROSSMAN, C.J. & HAYES, A.G. (1988). Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Europ. J. Pharmacol., 154, 85-87.
7. CARPENEDO, R., CHIARUGI, A., RUSSI, P., LOMBARDI, G., CARLA, V., PELLICCIARI, R., MORONI, F. & MATTOLI, L. (1994). Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anti-convulsant activities. Neuroscience, 61, 237-244.
8. CAROLL, F.Y., CHEUNG, N.S. & BEART, P.M. (1998). Investigations of non-NMDA receptor-induced toxicity in serum-free antioxidant-rich primary cultures of murine cerebellar granule cells. Neurochem. Intern., 33, 23-28.
9. CHIARUGI, A., CARPENEDO, R., MOLINA, M.T., MATTOLI, L., PELLICCIARI, R. & MORONI, F. (1995). Comparison of the neurochemical and behavioural effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J. Neurochem., 65, 1176-1183.
10. CHIARUGI, A., CARPENEDO, R. & MORONI, F. (1996). Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and kynurenase. J. Neurochem., 67, 692-698.
11. CLIFFORD, D.B., OLNEY, J.W., BENZ, A.M., FULLER, T.A. & ZORUMSKI, C.F. (1990). Ketamine, phencyclidine and MK-801 protect against kainic acid-induced serizure-related brain damage. Epilepsia, 31, 382-390.
12. CONNICK, J.H., HEYWOOD, G.C., SILLS, G.J., THOMPSON, G.G., BRODIE, M.J. & STONE, T.W. (1992). Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen. Pharmacol., 23, 235-239.
13. DEUPREE, D.L., TANG, X.W., YAROM, M., DICKMAN, E., KIRCH, R.D., SCHLOSS, J.V. & WU. J-Y. (1996). Studies of NMDA and non-NMDA-mediated neurotoxicity in cultured neurons. Neu-rochem. Intern., 29, 255-261.
14. ESPEY, M.G., CHERNYSHEV, O.N., REINHARD, Jr., J.F., NAMBOODIRI, M.A.A. & COLTON, C.A. (1997). Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport, 8, 431-434.
15. FARIELLO, R.G., GOLDEN. G.T., SMITH, G.G. & REYES, P.F. (1989). Potentiation of kainic acid epileptogenicity and sparing from neuronal damage by an NMDA receptor antagonist. Epilepsy Res., 3, 206-213.
16. FERKANY, J.W., ZACZEK, R. & COYLE, J.T. (1982). Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors. Nature, 298, 757-759.
17. FOSTER, A.C., GILL, R. & WOODRUFF, G.N. (1988). Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J. Neurosci., 8, 4745-4754.
18. GUARNIERI, T., VIRGILI, M., VILLANI, L., FACCHINETTI, F., CONTESTABILE, A. & MIGNANI, P. (1993). Pharmacological manipulation of the NMDA receptor differentially protects from kainic acid neuropathology: evaluation through ornithine decarboxylase induction, morphology and GFAP immunohistochemistry. Resto. Neurol. Neurosci., 5, 327-335.
19. HEYES, M.P., ACHIM, C.L., WILEY, C.A., MAJOR, E.O., SAITO, K. & MARKEY, S.P. (1996). Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J., 320, 595-597.
20. HEYES, M.P., SAITO, K. & MARKEY, S.P. (1992). Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid, Biochem. J., 283, 633-635.
21. JENSEN, J.B., SCHOUSBOE, A. & PICKERING, D.S. (1999). Role of desensitization and subunit expression for kainate receptor-mediated neurotoxicity in murine neocortical cultures. J. Neurosci. Res., 55, 208-217.
22. JONES, P.A., SMITH, R.A. & STONE, T.W. (1998). Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist. Brain Res., 800, 328-335.
23. JORGENSEN, M.B., FINSEN, B.R., JENSEN, M.B., CASTELLANO, B., DIEMER, N.H. & ZIMMER, J. (1993). Microglial and astroglial reactions to ischemic and kainic acid induced lesions of the adult rat hippocampus. Exp. Neurol., 120, 70-88.
24. KOHLER, C., SCHWARCZ, R. & FUXE, K. (1979). Hippocampal lesions indicate differences between the excitotoxic properties of acidic amino acids. Brain Res., 175, 366-371.
25. LASON, W., SIMPSON, J.N. & MCGINTY, J.F. (1988). Effects of D-(-)-2-aminophosphonovalerate on behavioural and histological changes induced by systemic kainic acid. Neurosci. Lett., 87, 23-28.
26. LASSMANN, H., PETSCHE, U., KITZ, K., BARAN, H., SPERK, G., SEITELBERGER, F. & HORNYKIEWICZ, O. (1984). The role of brain edema in epileptic brain damage induced by systemic kainic acid injection. Neuroscience, 13, 691-704.
27. LERNER-NATOLI, M., RONDOUIN, G., BELAIDI, M., BALDY-MOULINIER, M. & KAMENKA, J.M. (1991). TCP does not block kainic acid induced status epilepticus but reduces secondary hippocampal damage. Neurosci. Lett., 122, 174-178.
28. LIU, H.M., DE LIANG, L. & DONG, L.Y. (1996). Kainate-induced brain lesion: similar local and remote histopathological and molecular changes as in ischemic brain infarct. J. Neuropathol. Exp. Neurol., 55, 787-794.
29. MACGREGOR, D.G., MILLER, W. & STONE, T.W. (1993), Mediation of the neuroprotective action of R-phenylisopropyladenosine by a centrally located adenosine A1 receptor. Brit. J. Pharmacol., 110, 470-476.
30. MICHAELIS, E.K. (1998). Molecular Biology of glutamate receptors in the CNS and their role in excitotoxicity, oxidative stress and aging. Progr. Neurobiol., 54, 369-415.
31. MORONI, F., RUSSI, P., GALLO-MEZO, M.A., MONETI, G. & PELLICCIARI, R. (1991). Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine. J. Neurochem., 57, 1630-1635.
32. NADLER, J.V., PERRY, B.W. & COTMAN, C.W. (1978). Intraventricular kainic acid preferentially destroys hippocampal pyramidal cells. Nature, 271, 676-677.
33. NATALINI, B., MATTOLI, L., PELLICCIARI, R., CARPENEDO, R., CHIARUGI, A. & MORONI, F. (1995). Synthesis and activity of enantiopure (S) (m-nitrobenzoyl) alanine, potent kynurenine-3-hydroxylase inhibitor. Biorg. Med. Chem Lett., 5, 1451-1454.
34. OLNEY, J.W., RHEE, V. & HO, O.L. (1974). Kainic acid: a powerful neurotoxic analogue of glutamate. Brain Res., 77, 507-512.
35. PAI, K.S. & RAVINDRATH, V. (1992). Quisqualic acid-induced neurotoxicity is protected by NMDA and non-NMDA receptor antagonists. Neurosci. Lett., 143, 177-180.
36. PAXINOS, G. & WATSON, C. (1986). The rat brain in stereotaxie coordinates. Academic Press, London.
37. PELLICCIARI, R., NATALINI, B., COSTANTINO, G., MAHMOUD, M.R., MATTOLI, L. & SADEGHPOUR, B.M. (1994). Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J. Med. Chem., 31, 647-655.
38. PEMBERTON, L.A., KERRM, S.J., SMYTHE, G. & BREW, B.J. (1997). Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha and IFN-alpha. J. Inter. Cytokines Res., 17, 589-595.
39. PERKINS, M.N. & STONE, T.W. (1982). An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res., 247, 184-187.
40. PLANAS, A.M., SORIANO, M.A., FERRER, I. & FARRE, E.R. (1995). Kainic acid-induced heat shock protein-70, mRNA and protein expression is inhibited by MK-801 in certain rat brain regions. Europ. J. Neurosci., 7, 293-304.
41. RUSSI, P., ALESIANI, M., LOMBARDI, G., DAVOLIO, P., PELLICCIARI, R. & MORONI, F. (1992). Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J. Neurochem., 59, 2076-2080.
42. SCHWARCZ, R. & COYLE, J.T. (1977). Striatal lesions with kainic acid: neurochemical characteristics. Brain Res., 127, 235-249.
43. SCHWARCZ, R., WHETSELL, W.O. & MANGANO, R.M. (1983). Quinolinic acid: an endogenous metabolite that causes axon-sparing lesions. Science, 219, 316-318.
44. SCHWOB, J.E., FULLER, T., PRICE, J.L. & OLNEY, J.W. (1980). Widespread patterns of neuronal damage following systemic or intracerebral injections of kainic acid: a histological study. Neuroscience. 5, 991-1014.
45. SHINOZAKI, H. & KONISHI, S. (1970). Actions of several anthelmintics and insecticides on rat cortical neurons. Brain Rev., 24, 368-371.
46. SPECIALE, C. & SCHWARCZ, R. (1988). Effect of systemic kainate administration on cerebral quinolinic acid metabolism in the rat. Exp. Neurol., 99, 213-218.
47. SPECIALE, C., WU, H.Q., CINI, M., MARCONI, M., VARASI, M. & SCHWARCZ, R. (1996). (R,S)-3,4-dichlorobenzoylalanine (FCE28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Europ. J. Pharmacol., 315, 263-267.
48. SPERK, G., LASSMANN, H., BARAN, H., KISH, S.J., SEITELBERGER, F. & HORNYKIEWICZ, O. (1983). Kainic acid induced seizures: neurochemical and histopathological changes. Neuroscience, 10, 1301-1315.
49. STONE, T.W. (1993). Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Revs., 45, 309-379.
50. STONE, T.W. (2000). The development and therapeutic potential of kynurenic acid and kynurenine derivatives for CNS neuroprotection. Trends Pharmacol. Sci. in press.
51. STONE, T.W. & PERKINS, M.N. (1981). Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Europ. J. Pharmacol., 12, 411-412.
52. TAUCK, D.L. & NADLER, J.V. (1985). Evidence of functional mossy fibre sprouting in hippocampal formation of kainic acid-treated rats. J. Neurosci., 5, 1016-1022.
53. VECSEI, L., DIBO, G. & KISS, C. (1998). Neurotoxins and neurodegenerative disorders. Neurotoxicology, 19, 511-514.
54. VIRGILI, M., MIGANI, P., CONTESTABILE, A & BARNABEI. O. (1992). Protection from kainic acid neuropathological syndrome by NMDA receptor antagonists: effects of MK-801 and CGP 39551 on neurotransmitter and glial markers. Neuroscience, 31, 469-474.
55. WOLF, G., FISCHER, S., HASS, P., ABICHT, K. & KEILHOFF, G. (1991). Magnesium sulphate subcutaneously injected protects against kainate-induced convulsions and neurodegeneration: in vivo study on the rat hippocampus. Neuroscience, 43, 31-34.